Studies show that GW3965, an LXR-α agonist, amplifies its tumor-suppressing actions, while Afatinib, an EGFR inhibitor, promotes LXR-α expression by blocking AKT activation and upregulating FOXO3A. This evidence concerns the gene NR1H3 and neoplasm.